Coeptis Therapeutics Inc

NASDAQ:COEP USA Biotechnology
Market Cap
$56.40 Million
Market Cap Rank
#21330 Global
#7654 in USA
Share Price
$11.70
Change (1 day)
-2.50%
52-Week Range
$7.05 - $18.80
All Time High
$18.80
About

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more

Coeptis Therapeutics Inc - Asset Resilience Ratio

Latest as of September 2025: 2.59%

Coeptis Therapeutics Inc (COEP) has an Asset Resilience Ratio of 2.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets
$421.70K
Cash + Short-term Investments
Total Assets
$16.28 Million
All company assets
Resilience Assessment
Low
Financial Resilience Level

Asset Resilience Ratio Trend (None–None)

This chart shows how Coeptis Therapeutics Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.

Liquid Assets Composition Over Time

This chart breaks down Coeptis Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $421.70K 2.59%
Total Liquid Assets $421.70K 2.59%

Asset Resilience Insights

  • Limited Liquidity: Coeptis Therapeutics Inc maintains only 2.59% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Coeptis Therapeutics Inc Industry Peers by Asset Resilience Ratio

Compare Coeptis Therapeutics Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
MedPacto Inc
KQ:235980
Biotechnology 49.82%
Shenzhen CAU Technology Co Ltd
SHE:000004
Biotechnology 6.20%
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
Biotechnology 6.88%
Nanhua Bio Medicine Co Ltd
SHE:000504
Biotechnology 11.93%
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
Biotechnology 0.03%
Chengzhi Shareholding Co Ltd
SHE:000990
Biotechnology 6.73%
Hualan Biological EngineeringInc
SHE:002007
Biotechnology 14.68%
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
Biotechnology 4.35%

Annual Asset Resilience Ratio for Coeptis Therapeutics Inc (None–None)

The table below shows the annual Asset Resilience Ratio data for Coeptis Therapeutics Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
No yearly data available.
pp = percentage points